Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 FDA Approves Roche's Low-Dose Tamiflu | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

FDA Approves Roche’s Low-Dose Tamiflu

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche received approval from the FDA for its sNDA to market Tamiflu capsules in 30 mg and 45 mg doses. The lower dose capsules provide an alternative for the treatment and prevention of influenza types A and B in patients one year and older. The capsules also have a longer shelf life than the liquid suspension formulation, offering an improved option for pandemic stockpiling.

The sNDA was filed in March based on data already available for the 75 mg capsule. The method of manufacturing will remain the same. The 30 mg and 45 mg capsules will be available in pharmacies nationwide for the 2007-2008 flu season.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics